OSCR stock snaps 6-day slide ahead of Q4 results: Can the rebound survive post-ACA subsidy fears?
I'm PortAI, I can summarize articles.
Oscar Health, Inc. (OSCR) ended a six-day losing streak, closing at $12.66, as investors anticipate quarterly results showing revenue growth but widening losses. Q4 revenue is expected to reach $3.12 billion, up from $2.99 billion, while adjusted EBITDA losses may increase to $217.8 million. Analysts have mixed ratings, with a consensus 'Hold' and price targets ranging from $12 to $25. ACA enrollment trends pose risks, but Oscar remains optimistic about profitability by 2026. Retail sentiment on Stocktwits is bullish, with users expressing confidence in the company's potential to exceed expectations.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments